Press Releases

Thursday, 10. May 2012

Antisense Pharma Internationalizes Management Board

Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies  mehr

Wednesday, 29. February 2012

Antisense Pharma to expand to first-line treatment with trabedersen; 2nd line Phase III high grade glioma trial terminated due to patient recruitment issues

Antisense Pharma announces that the Phase III trial for recurrent or refractory anaplastic astrocytoma (AA) or sec-ondary glioblastoma (GBM) was terminated due to...  mehr

Wednesday, 11. January 2012

Special Issue: Transforming Growth Factor Beta (TGF-β) as a Target in Oncology

Current Pharmaceutical Biotechnology has published reviews from more than 25 internationally renowned TGF-β experts. Antisense Pharma’s founder, Dr. Karl-Hermann Schlingensiepen, was entrusted with guest editor ship.  mehr